Targeted delivery of doxorubicin into tumor cells by nanostructured lipid carriers conjugated to anti-EGFRvIII monoclonal antibody.

Artif Cells Nanomed Biotechnol 2018 Feb 15;46(1):89-94. Epub 2017 Mar 15.

a Department of Medical Biochemistry, Faculty of Medicine , Tehran University of Medical Sciences , Tehran , Iran.

Epidermal growth factor receptor variant III (EGFRvIII) is the most common variant of the EGF receptor in many human tumors. This variant is tumor specific and highly immunogenic, thus, it can be used as a target for targeted drug delivery toward tumor cells. The major aim of this study was to develop an EGFRvIII-mediated drug delivery system by anti-EGFRvIII monoclonal antibody (MAb) conjugated to doxorubicin (Dox)-loaded nanostructured lipid carriers (NLC) to enhance the targeting specificity and cytotoxic effect of Dox on EGFRvIII-overexpressing cell line. In our study, Dox was chosen as a hydrophobic cytotoxic drug and drug-loaded nanostructured lipid carriers (Dox-NLC) was prepared by solvent emulsification/evaporation method. In order to conjugate anti-EGFRvIII MAb to Dox-NLC, DSPE-PEG2000-NHS (1,2-distearoylphosphatidylethanolamine-polyethylene glycol 2000-NHS) was used as a linker. Physicochemical characteristics of antibody conjugated Dox-NLC (MAb-Dox-NLC), including particle size, zeta potential, entrapment efficiency and in vitro Dox release were investigated. Cytotoxicity of MAb-Dox-NLC against NIH-3T3 and HC2 20d2/c (EGFRvIII-transfected NIH-3T3) cell lines was evaluated. The MAb-Dox-NLC appeared to enhance the cytotoxic activity of targeted NLC against HC2 20d2/c cells. The cellular uptake percentage of targeted NLC by HC2 20d2/c cells was higher than that of NIH-3T3 cells, indicating that EGFRvIII can specifically target HC2 20d2/c cells. In conclusion, anti-EGFRvIII MAb-targeted NLC may be considered as an effective nanocarrier for targeted drug delivery.

Download full-text PDF

Source
http://dx.doi.org/10.1080/21691401.2017.1296847DOI Listing
February 2018
24 Reads

Publication Analysis

Top Keywords

hc2 20d2/c
16
drug delivery
12
nanostructured lipid
12
20d2/c cells
12
lipid carriers
12
monoclonal antibody
8
anti-egfrviii monoclonal
8
targeted drug
8
targeted nlc
8
nlc hc2
8
tumor cells
8
cells
6
targeted
5
physicochemical characteristics
4
dspe-peg2000-nhs 12-distearoylphosphatidylethanolamine-polyethylene
4
linker physicochemical
4
12-distearoylphosphatidylethanolamine-polyethylene glycol
4
glycol 2000-nhs
4
2000-nhs linker
4
conjugated dox-nlc
4

Similar Publications